CRLX101
CRLX101 is an experimental approach to cancer chemotherapy that is under investigation in human trials. It is an example of a nanomedicine.
The agent represents a nanoparticle conjugate that consists of a drug delivery molecule, namely a cyclodextrin-based polymer (CDP) and an anti-cancer compound (camptothecin). It was developed by Mark E. Davis, professor of Chemical Engineering at the California Institute of Technology, and associates at Insert Therapeutics, Inc., now Calando Pharmaceuticals, Inc., hence the original name "IT-101". Its novel delivery mode allows the agent, and thus the toxic anti-cancer component, to be preferentially accumulated in cancer tissue. In turn, toxic side effect are expected to be reduced. The technology was licensed by Calando and Caltech to Cerulean Pharma, in 2009.
Clinical trials
[edit]The Phase 1/2a clinical trial was conducted at the City of Hope National Medical Center, the Translational Genomics Research Institute, and San Juan Oncology Associates.[1]
Media
[edit]IT-101 and Mark E. Davis were included in a PBS documentary titled Survival.[2]
References
[edit]- ^ Weiss GJ, Chao J, Neidhart JD, Ramanathan RK, Bassett D, Neidhart JA, Choi CH, Chow W, Chung V, Forman SJ, Garmey E, Hwang J, Kalinoski DL, Koczywas M, Longmate J, Melton RJ, Morgan R, Oliver J, Peterkin JJ, Ryan JL, Schluep T, Synold TW, Twardowski P, Davis ME, Yen Y (2013). "First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies". Invest. New Drugs. 31 (4): 986–1000. doi:10.1007/s10637-012-9921-8. PMC 3774600. PMID 23397498.
- ^ "Survival". thirteen.org.
External links
[edit]- Calando Pharmaceuticals, Inc. was Insert Therapeutics, Inc.
- Cerulean Pharma Inc. CRLX101 licensee and current developer
- Q&A with Mark Davis on Thirteen
- Mark E. Davis Research Group at California Institute of Technology